Get the Stockscreener App
1.34
4.96%
-0.07
After Hours:
1.37
0.03
+2.24%
Traws Pharma Inc stock is traded at $1.34, with a volume of 24,198.
It is down -4.96% in the last 24 hours and down -44.86% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$1.41
Open:
$1.41
24h Volume:
24,198
Relative Volume:
0.06
Market Cap:
$10.71M
Revenue:
$2.90M
Net Income/Loss:
$87.91M
P/E Ratio:
0.0858
EPS:
15.6103
Net Cash Flow:
$-26.93M
1W Performance:
+0.75%
1M Performance:
-44.86%
6M Performance:
-13.55%
1Y Performance:
-83.40%
1-Day Range:
$1.34
$1.4403
1-Week Range:
$1.26
$1.4403
52-Week Range:
$0.97
$9.31
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.34 | 11.27M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Fed Meeting: Is Traws Pharma Inc. stock a buy before product launches2025 Market WrapUp & Weekly Market Pulse Updates - ulpravda.ru
How resilient is Traws Pharma Inc. stock in market downturnsTrade Exit Report & Short-Term Trading Alerts - ulpravda.ru
Why Traws Pharma Inc. stock remains on watchlists2025 Market Outlook & Consistent Profit Trade Alerts - ulpravda.ru
Is Traws Pharma Inc. stock cheap at current valuationMarket Activity Report & Community Trade Idea Sharing - ulpravda.ru
How Traws Pharma Inc. stock compares to industry benchmarksPortfolio Risk Report & High Accuracy Trade Signal Alerts - ulpravda.ru
Comparing Miravant Medical Technologies (OTCMKTS:MRVT) and Traws Pharma (NASDAQ:TRAW) - Defense World
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances - MSN
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors - Moscow-Pullman Daily News
Traws Pharma (NASDAQ:TRAW) Shares Down 3.5% – Time to Sell? - Defense World
How Traws Pharma Inc. stock compares to growth peersTechnical Resistance Breaks & Fast Growing Capital Gains - bollywoodhelpline.com
CLARKE TRAFFORD Insider Trades - Nasdaq
Why Traws Pharma Inc. (0T20) stock stays on top picksAnalyst Upgrades & Master Stock Selection - Bollywood Helpline
New COVID Pill Shows Promise Against Paxlovid in Early Head-to-Head Trial - MyChesCo
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Is Traws Pharma Inc a good long term investmentRetail Trading Trends & High Return Wealth Building - earlytimes.in
Momentum Shift: Will Traws Pharma Inc. (0T20) stock benefit from mergersMarket Sentiment Report & Real-Time Buy Zone Alerts - Улправда
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir - MSN
How Traws Pharma Inc. stock performs during Fed tightening cyclesJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - Улправда
How Traws Pharma Inc. stock reacts to global recession fears2025 Growth vs Value & AI Driven Stock Reports - Улправда
Why Traws Pharma Inc. (0T20) stock stays on buy lists2025 Biggest Moves & Consistent Profit Trading Strategies - DonanımHaber
Aug Momentum: How Traws Pharma Inc. stock reacts to global recession fearsWeekly Investment Recap & Free Technical Confirmation Trade Alerts - Улправда
Will Traws Pharma Inc. (0T20) stock profit from fiscal stimulusJuly 2025 Highlights & Real-Time Volume Surge Alerts - Улправда
Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid - Benzinga
Traws Pharma, Inc. Announces Positive Interim Data for Ratutrelvir in COVID-19 Study - TradingView — Track All Markets
Traws Pharma Reports Promising Interim Data for Ratutrelvir, Showing Favorable Profile Compared to PAXLOVID™ in COVID-19 Treatment - Quiver Quantitative
Traws Pharma (NASDAQ: TRAW) highlights positive Phase 2 COVID data results - Stock Titan
Traws Pharma Reports Positive Interim Clinical Data - One News Page
Ratutrelvir shows promising interim results in COVID-19 trial - Investing.com
Traws Pharma (TRAW) reports director RSU and stock option awards - Stock Titan
[Form 4] Traws Pharma, Inc. Insider Trading Activity - Stock Titan
Traws Pharma, Inc. (TRAW) director awarded RSUs and stock options in 2025 grant - Stock Titan
Traws Pharma (TRAW) director reports equity awards details in Form 4 filing - Stock Titan
Traws Pharma (NASDAQ: TRAW) CEO reports new RSU and stock option awards - Stock Titan
Traws Pharma (TRAW) CSO receives new RSUs and stock options grant - Stock Titan
Traws Pharma (NASDAQ: TRAW) discloses CMO equity grants of stock and options - Stock Titan
Traws Pharma (TRAW) insider granted RSUs and options on 12/12/2025 as equity awards - Stock Titan
Traws Pharma (Nasdaq: TRAW) approves stock option and RSU grants for top executives - Stock Titan
Traws Pharma Earnings Notes - Trefis
Published on: 2025-12-12 06:22:07 - moha.gov.vn
Traws Pharma (TRAW) – Analysts’ Recent Ratings Changes - Defense World
Traws Pharma (NASDAQ:TRAW) Upgraded at Zacks Research - Defense World
0T20 Forecast — Price Target — Prediction for 2026 - TradingView
Traws Pharma (NASDAQ:TRAW) Cut to “Sell” at Wall Street Zen - Defense World
HC Wainwright Estimates Traws Pharma Q4 Earnings - Defense World
Can Traws Pharma Inc. (0T20) stock sustain institutional flowsTrade Risk Assessment & Consistent Growth Equity Picks - Newser
What earnings margins imply for Traws Pharma Inc. (0T20) stock2025 Pullback Review & Scalable Portfolio Growth Methods - Newser
HC Wainwright Begins Coverage on Traws Pharma (NASDAQ:TRAW) - Defense World
Is Traws Pharma Inc. stock trading near support levelsTrade Performance Summary & AI Powered Buy/Sell Recommendations - newser.com
How Traws Pharma Inc. (0T20) stock behaves under inflation pressureJuly 2025 Outlook & Precise Trade Entry Recommendations - Newser
Will Traws Pharma Inc. (0T20) stock benefit from sector leadership2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Why ETFs are accumulating Traws Pharma Inc. (0T20) stockQuarterly Earnings Report & Entry and Exit Point Strategies - Newser
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):